Advertisement
NRIX vs RCUS
Which Stock Would AI Choose? Nurix Therapeutics (NRIX) vs. Arcus Biosciences (RCUS) Stock Comparison
Key Takeaways
- Both NRIX and RCUS are clinical-stage biotechnology companies with concentrated pipelines and no recurring product revenue.
- Nurix is centered on targeted protein degradation (TPD) and its lead BTK (Bruton's tyrosine kinase) degrader, bexobrutideg, while Arcus is built around its HIF-2α (hypoxia-inducible factor 2-alpha) inhibitor, casdatifan, in kidney cancer.
- Nurix recently reported a one-time profit driven by a large Roche collaboration payment, whereas Arcus continues to post quarterly losses supported by partnership funding.
- Both stocks carry heavy reliance on partners (Roche, Sanofi, Gilead, and Pfizer for Nurix; Gilead and Taiho for Arcus), making collaboration economics a key variable.
- Relative performance and sentiment have diverged recently, with Nurix's cash runway extending into 2029 and Arcus's casdatifan data drawing renewed analyst optimism.
Introduction
This stock comparison examines two mid-cap oncology-focused biotechnology companies, Nurix Therapeutics (NRIX) and Arcus Biosciences (RCUS), each pursuing a distinct scientific approach to treating cancer. Because both firms are pre-commercial and depend heavily on clinical readouts and partnership funding, their market positioning and relative performance are shaped more by pipeline momentum than by current earnings. This comparison may be most relevant to growth-oriented investors and traders comfortable with the elevated volatility and binary risk typical of the biotechnology sector, as well as those tracking how AI-driven analysis assesses trend consistency and catalyst positioning across two structurally similar but scientifically different businesses.
NRIX Overview and Recent Performance
Nurix Therapeutics (NRIX) is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), a mechanism that marks disease-causing proteins for destruction rather than simply blocking them. Its lead program, bexobrutideg, is an oral BTK (Bruton's tyrosine kinase) degrader being advanced through late-stage trials in blood cancers such as relapsed/refractory chronic lymphocytic leukemia (CLL). In recent weeks, Nurix's market positioning has been reshaped by a global collaboration with Roche, which included a roughly $700 million upfront payment within a deal carrying up to $2.3 billion in total consideration. That payment drove a sharp swing to reported profitability in the most recent quarter, with revenue of approximately $673 million versus roughly $7.9 million a year earlier. However, analysts widely noted that this "beat" reflects a non-recurring license payment rather than sustainable product sales, and the underlying business remains cash-flow negative. Nurix also holds collaborations with Sanofi, Gilead, and Pfizer, and reported roughly $1.1 billion in cash and marketable securities, supporting a runway into the second half of 2029. Its valuation, near a $2.3 billion market capitalization, remains closely tied to bexobrutideg's clinical success.
RCUS Overview and Recent Performance
Arcus Biosciences (RCUS) is a clinical-stage biotechnology company focused on immuno-oncology and inflammatory diseases. Its lead asset is casdatifan, a HIF-2α (hypoxia-inducible factor 2-alpha) inhibitor being developed for clear cell renal cell carcinoma (ccRCC), a common form of kidney cancer. In recent market activity, Arcus released data from its ARC-20 study showing a median overall survival of roughly 35 months in late-line kidney cancer patients, alongside combination data that analysts described as demonstrating a potency advantage over Merck's approved HIF-2α inhibitor, belzutifan. The initial reaction was mixed, but several firms, including Mizuho and Leerink Partners, issued positive commentary, with Mizuho citing a peak sales opportunity and maintaining an Outperform rating with a $47 price target. Arcus has no approved products generating revenue and continues to report quarterly losses, funded in part through collaborations with Gilead and Taiho. Its market capitalization stands near $3.1 billion, with the stock's valuation concentrated on casdatifan's ability to become a foundational therapy across multiple lines of kidney cancer treatment.
Trending AI Robots
For traders seeking a data-driven perspective on names like NRIX and RCUS, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, but only those best suited to current market conditions earn a place in this section. These bots vary widely in trading style, strategy, timeframe, performance, and the sets of tickers they cover, allowing users to compare statistics and historical results across different approaches. The platform surfaces the robots currently gaining traction, helping investors evaluate which automated systems are demonstrating relative strength in the present environment. Exploring the Trending AI Robots section can provide useful context on how algorithmic models are positioning across the market today.
Head-to-Head Comparison
While both companies operate in oncology, their business models and growth drivers diverge meaningfully. Nurix's (NRIX) TPD platform is validated by one of the sector's largest collaborations, with Roche sharing development costs and co-commercializing bexobrutideg, which reduces near-term capital risk but also caps Nurix's U.S. upside through profit sharing. Arcus (RCUS), by contrast, has retained full ownership of casdatifan and is using capital-efficient clinical collaborations to broaden its development footprint. On momentum, Nurix benefits from a substantially extended cash runway and a recently de-risked lead asset, while Arcus is generating fresh, positive clinical data but remains heavily reliant on upcoming readouts. Risk profiles also differ: Nurix faces execution risk around a single pivotal BTK degrader against entrenched BTK inhibitors, whereas Arcus faces competition in a kidney cancer market where Merck's belzutifan is already established. Market sentiment has favored different catalysts, with Nurix's balance sheet strength versus Arcus's data-driven pipeline narrative representing the central trade-off.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and catalyst positioning, Tickeron's AI would likely express a near-term preference for Nurix Therapeutics (NRIX). The combination of a de-risking Roche partnership, a cash runway extending into 2029, and a lead asset already in registrational trials contributes to a more stable risk profile. Arcus Biosciences (RCUS) presents a compelling longer-term catalyst story around casdatifan, but its positioning remains more sensitive to binary clinical outcomes and competitive dynamics. This assessment reflects a probabilistic reading of relative positioning rather than a definitive prediction, and both names retain meaningful upside and downside scenarios tied to future data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRIX is a StrongBuy and RCUS is a Hold.
NRIX in upward trend: price rose above 50-day moving average on October 20, 2026
NRIX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on NRIX as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on October 14, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in 204 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for NRIX moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 20 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NRIX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.707) is normal, around the industry mean (2.988). P/E Ratio (-7.520) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCUS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 21, 2026
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where RCUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for RCUS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 219 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for RCUS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.242) is normal, around the industry mean (2.988). P/E Ratio (-4.848) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NRIX | RCUS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 36 | 58 | |
P/E GROWTH RATING 1..100 | 58 | 24 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NRIX's Valuation (57) in the null industry is in the same range as RCUS (64) in the Pharmaceuticals Major industry. This means that NRIX’s stock grew similarly to RCUS’s over the last 12 months.
NRIX's Profit vs Risk Rating (100) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that NRIX’s stock grew similarly to RCUS’s over the last 12 months.
NRIX's SMR Rating (98) in the null industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that NRIX’s stock grew similarly to RCUS’s over the last 12 months.
NRIX's Price Growth Rating (36) in the null industry is in the same range as RCUS (58) in the Pharmaceuticals Major industry. This means that NRIX’s stock grew similarly to RCUS’s over the last 12 months.
RCUS's P/E Growth Rating (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for NRIX (58) in the null industry. This means that RCUS’s stock grew somewhat faster than NRIX’s over the last 12 months.
| NRIX | RCUS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| Advances ODDS (%) | 3 days ago 82% | 3 days ago 78% |
| Declines ODDS (%) | 10 days ago 87% | 10 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NRIX’s FA Score shows that 0 FA rating(s) are green while RCUS’s FA Score has 1 green FA rating(s).
- NRIX’s FA Score: 0 green, 5 red.
- RCUS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NRIX’s TA Score shows that 4 TA indicator(s) are bullish while RCUS’s TA Score has 4 bullish TA indicator(s).
- NRIX’s TA Score: 4 bullish, 6 bearish.
- RCUS’s TA Score: 4 bullish, 4 bearish.
Price Growth
NRIX (@Biotechnology) experienced а +9.93% price change this week, while RCUS (@Biotechnology) price change was -15.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
NRIX is expected to report earnings on Feb 17, 2027.
RCUS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NRIX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NRIX has been loosely correlated with KYMR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NRIX jumps, then KYMR could also see price increases.
| Ticker / NAME | Correlation To NRIX | 1D Price Change % | ||
|---|---|---|---|---|
| NRIX | 100% | -0.31% | ||
| KYMR - NRIX | 59% Loosely correlated | -0.73% | ||
| GPCR - NRIX | 48% Loosely correlated | -3.80% | ||
| DYN - NRIX | 46% Loosely correlated | -1.23% | ||
| SVRA - NRIX | 44% Loosely correlated | -1.89% | ||
| AGIO - NRIX | 44% Loosely correlated | +1.47% | ||
More | ||||
RCUS and
Correlation & Price change
A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To RCUS | 1D Price Change % | ||
|---|---|---|---|---|
| RCUS | 100% | -19.58% | ||
| VIR - RCUS | 49% Loosely correlated | -1.58% | ||
| XNCR - RCUS | 49% Loosely correlated | +0.88% | ||
| KURA - RCUS | 46% Loosely correlated | -1.00% | ||
| NRIX - RCUS | 44% Loosely correlated | -0.31% | ||
| BCAX - RCUS | 44% Loosely correlated | -2.40% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GK | 28.24 | 0.25 | +0.88% |
| AdvisorShares Gerber Kawasaki ETF (GK) | |||
| REGL | 89.70 | 0.02 | +0.02% |
| ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) | |||
| TBFC | 28.68 | N/A | N/A |
| Brinsmere Fund Conservative ETF (TBFC) | |||
| ZJAN | 28.52 | -0.01 | -0.03% |
| Innovator Equity Defined Protection ETF - 1 Yr January | |||
| TSMZ | 7.55 | -0.12 | -1.54% |
| Direxion Daily TSM Bear 1X ETF (TSMZ) | |||